nodes	percent_of_prediction	percent_of_DWPC	metapath
Gabapentin—Ethinamate—CA1—esophageal cancer	0.0271	0.569	CrCbGaD
Gabapentin—Ethinamate—CA2—esophageal cancer	0.0205	0.431	CrCbGaD
Gabapentin—CACNA2D2—neck—esophageal cancer	0.0115	0.192	CbGeAlD
Gabapentin—CACNA2D2—Adrenaline,noradrenaline inhibits insulin secretion—GNG7—esophageal cancer	0.00756	0.0534	CbGpPWpGaD
Gabapentin—BCAT1—trachea—esophageal cancer	0.00753	0.126	CbGeAlD
Gabapentin—CACNA1B—lung—esophageal cancer	0.00688	0.115	CbGeAlD
Gabapentin—BCAT1—Validated targets of C-MYC transcriptional activation—GAPDH—esophageal cancer	0.00577	0.0408	CbGpPWpGaD
Gabapentin—CACNA2D1—Arrhythmogenic Right Ventricular Cardiomyopathy—ACTB—esophageal cancer	0.00562	0.0397	CbGpPWpGaD
Gabapentin—CACNA2D1—Arrhythmogenic Right Ventricular Cardiomyopathy—CTNNA1—esophageal cancer	0.00552	0.039	CbGpPWpGaD
Gabapentin—BCAT1—lung—esophageal cancer	0.00541	0.0904	CbGeAlD
Gabapentin—CACNA1B—Calcium Regulation in the Cardiac Cell—ATP1B2—esophageal cancer	0.00502	0.0355	CbGpPWpGaD
Gabapentin—CACNA2D2—lung—esophageal cancer	0.00496	0.0829	CbGeAlD
Gabapentin—CACNA1B—lymph node—esophageal cancer	0.00471	0.0786	CbGeAlD
Gabapentin—CACNA1B—Calcium Regulation in the Cardiac Cell—FKBP1A—esophageal cancer	0.00465	0.0329	CbGpPWpGaD
Gabapentin—BCAT1—Validated targets of C-MYC transcriptional activation—ENO1—esophageal cancer	0.00455	0.0321	CbGpPWpGaD
Gabapentin—BCAT1—lymph node—esophageal cancer	0.0037	0.0618	CbGeAlD
Gabapentin—CACNA2D1—lung—esophageal cancer	0.00357	0.0596	CbGeAlD
Gabapentin—ADORA1—lung—esophageal cancer	0.00344	0.0575	CbGeAlD
Gabapentin—CACNA2D2—lymph node—esophageal cancer	0.0034	0.0567	CbGeAlD
Gabapentin—CACNA2D2—Regulation of insulin secretion—GNG7—esophageal cancer	0.00337	0.0238	CbGpPWpGaD
Gabapentin—BCAT1—Validated targets of C-MYC transcriptional activation—SMAD4—esophageal cancer	0.00318	0.0225	CbGpPWpGaD
Gabapentin—CACNA2D2—Arrhythmogenic Right Ventricular Cardiomyopathy—ACTB—esophageal cancer	0.00313	0.0221	CbGpPWpGaD
Gabapentin—CACNA2D2—Arrhythmogenic Right Ventricular Cardiomyopathy—CTNNA1—esophageal cancer	0.00308	0.0218	CbGpPWpGaD
Gabapentin—BCAT1—Validated targets of C-MYC transcriptional activation—BAX—esophageal cancer	0.00301	0.0213	CbGpPWpGaD
Gabapentin—CACNA1B—Calcium Regulation in the Cardiac Cell—GNG7—esophageal cancer	0.003	0.0212	CbGpPWpGaD
Gabapentin—CACNA1B—Calcium Regulation in the Cardiac Cell—SFN—esophageal cancer	0.00297	0.021	CbGpPWpGaD
Gabapentin—CACNA2D2—Integration of energy metabolism—GNG7—esophageal cancer	0.00265	0.0187	CbGpPWpGaD
Gabapentin—CACNA2D1—lymph node—esophageal cancer	0.00244	0.0408	CbGeAlD
Gabapentin—CACNA1B—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00237	0.0167	CbGpPWpGaD
Gabapentin—CACNA1B—Calcium Regulation in the Cardiac Cell—CALR—esophageal cancer	0.00237	0.0167	CbGpPWpGaD
Gabapentin—ADORA1—lymph node—esophageal cancer	0.00236	0.0393	CbGeAlD
Gabapentin—BCAT1—Amino acid and derivative metabolism—PSME1—esophageal cancer	0.00224	0.0158	CbGpPWpGaD
Gabapentin—BCAT1—Amino acid and derivative metabolism—PSME2—esophageal cancer	0.00224	0.0158	CbGpPWpGaD
Gabapentin—CACNA1B—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.00222	0.0157	CbGpPWpGaD
Gabapentin—BCAT1—Validated targets of C-MYC transcriptional activation—CREBBP—esophageal cancer	0.00213	0.015	CbGpPWpGaD
Gabapentin—ADORA1—Circadian rythm related genes—CRTC1—esophageal cancer	0.00198	0.014	CbGpPWpGaD
Gabapentin—CACNA1B—Neuronal System—GNG7—esophageal cancer	0.00181	0.0128	CbGpPWpGaD
Gabapentin—CACNA1B—Neuronal System—ALDH2—esophageal cancer	0.0017	0.012	CbGpPWpGaD
Gabapentin—CACNA2D2—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00157	0.0111	CbGpPWpGaD
Gabapentin—CACNA2D2—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.00147	0.0104	CbGpPWpGaD
Gabapentin—BCAT1—Validated targets of C-MYC transcriptional activation—EP300—esophageal cancer	0.00145	0.0102	CbGpPWpGaD
Gabapentin—BCAT1—Validated targets of C-MYC transcriptional activation—MYC—esophageal cancer	0.00126	0.00892	CbGpPWpGaD
Gabapentin—CACNA2D2—Neuronal System—GNG7—esophageal cancer	0.0012	0.00849	CbGpPWpGaD
Gabapentin—CACNA2D2—Neuronal System—ALDH2—esophageal cancer	0.00113	0.00796	CbGpPWpGaD
Gabapentin—Dysphagia—Capecitabine—esophageal cancer	0.00106	0.00141	CcSEcCtD
Gabapentin—ADORA1—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00106	0.00747	CbGpPWpGaD
Gabapentin—Thrombophlebitis—Methotrexate—esophageal cancer	0.00106	0.00141	CcSEcCtD
Gabapentin—Diabetes mellitus—Methotrexate—esophageal cancer	0.00105	0.0014	CcSEcCtD
Gabapentin—BCAT1—Metabolism—BLVRB—esophageal cancer	0.00105	0.0074	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—SLC52A3—esophageal cancer	0.00105	0.0074	CbGpPWpGaD
Gabapentin—Bronchospasm—Capecitabine—esophageal cancer	0.00104	0.00139	CcSEcCtD
Gabapentin—Polyuria—Methotrexate—esophageal cancer	0.00104	0.00139	CcSEcCtD
Gabapentin—Immune system disorder—Cisplatin—esophageal cancer	0.00104	0.00139	CcSEcCtD
Gabapentin—Mediastinal disorder—Cisplatin—esophageal cancer	0.00104	0.00138	CcSEcCtD
Gabapentin—BCAT1—Validated targets of C-MYC transcriptional activation—TP53—esophageal cancer	0.00104	0.00733	CbGpPWpGaD
Gabapentin—Sweating increased—Capecitabine—esophageal cancer	0.00103	0.00138	CcSEcCtD
Gabapentin—Angina pectoris—Capecitabine—esophageal cancer	0.00103	0.00138	CcSEcCtD
Gabapentin—Bronchitis—Capecitabine—esophageal cancer	0.00102	0.00136	CcSEcCtD
Gabapentin—Alopecia—Cisplatin—esophageal cancer	0.00102	0.00136	CcSEcCtD
Gabapentin—Hepatic failure—Methotrexate—esophageal cancer	0.00102	0.00135	CcSEcCtD
Gabapentin—Malnutrition—Cisplatin—esophageal cancer	0.001	0.00134	CcSEcCtD
Gabapentin—Erythema—Cisplatin—esophageal cancer	0.001	0.00134	CcSEcCtD
Gabapentin—Dysuria—Capecitabine—esophageal cancer	0.000992	0.00132	CcSEcCtD
Gabapentin—Renal failure acute—Methotrexate—esophageal cancer	0.00099	0.00132	CcSEcCtD
Gabapentin—Flatulence—Cisplatin—esophageal cancer	0.000988	0.00132	CcSEcCtD
Gabapentin—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000986	0.00131	CcSEcCtD
Gabapentin—ADORA1—G alpha (i) signalling events—GNG7—esophageal cancer	0.000978	0.00691	CbGpPWpGaD
Gabapentin—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000969	0.00129	CcSEcCtD
Gabapentin—Weight increased—Capecitabine—esophageal cancer	0.000966	0.00129	CcSEcCtD
Gabapentin—Muscle spasms—Cisplatin—esophageal cancer	0.000964	0.00128	CcSEcCtD
Gabapentin—Weight decreased—Capecitabine—esophageal cancer	0.00096	0.00128	CcSEcCtD
Gabapentin—Hyperglycaemia—Capecitabine—esophageal cancer	0.000957	0.00127	CcSEcCtD
Gabapentin—Pneumonia—Capecitabine—esophageal cancer	0.000952	0.00127	CcSEcCtD
Gabapentin—Infestation NOS—Capecitabine—esophageal cancer	0.000946	0.00126	CcSEcCtD
Gabapentin—Infestation—Capecitabine—esophageal cancer	0.000946	0.00126	CcSEcCtD
Gabapentin—Vision blurred—Cisplatin—esophageal cancer	0.000945	0.00126	CcSEcCtD
Gabapentin—Depression—Capecitabine—esophageal cancer	0.000943	0.00126	CcSEcCtD
Gabapentin—Tremor—Cisplatin—esophageal cancer	0.00094	0.00125	CcSEcCtD
Gabapentin—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000938	0.00125	CcSEcCtD
Gabapentin—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000933	0.00124	CcSEcCtD
Gabapentin—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000933	0.00124	CcSEcCtD
Gabapentin—Lethargy—Methotrexate—esophageal cancer	0.000933	0.00124	CcSEcCtD
Gabapentin—Ill-defined disorder—Cisplatin—esophageal cancer	0.000931	0.00124	CcSEcCtD
Gabapentin—Renal failure—Capecitabine—esophageal cancer	0.00093	0.00124	CcSEcCtD
Gabapentin—Myocardial infarction—Capecitabine—esophageal cancer	0.000927	0.00124	CcSEcCtD
Gabapentin—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000927	0.00124	CcSEcCtD
Gabapentin—Anaemia—Cisplatin—esophageal cancer	0.000927	0.00123	CcSEcCtD
Gabapentin—Stomatitis—Capecitabine—esophageal cancer	0.000922	0.00123	CcSEcCtD
Gabapentin—Jaundice—Capecitabine—esophageal cancer	0.000922	0.00123	CcSEcCtD
Gabapentin—Conjunctivitis—Capecitabine—esophageal cancer	0.00092	0.00122	CcSEcCtD
Gabapentin—Urinary tract infection—Capecitabine—esophageal cancer	0.00092	0.00122	CcSEcCtD
Gabapentin—Osteoarthritis—Methotrexate—esophageal cancer	0.000914	0.00122	CcSEcCtD
Gabapentin—Malaise—Cisplatin—esophageal cancer	0.000905	0.0012	CcSEcCtD
Gabapentin—Haematuria—Capecitabine—esophageal cancer	0.000902	0.0012	CcSEcCtD
Gabapentin—Leukopenia—Cisplatin—esophageal cancer	0.000898	0.0012	CcSEcCtD
Gabapentin—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000895	0.00119	CcSEcCtD
Gabapentin—Epistaxis—Capecitabine—esophageal cancer	0.000892	0.00119	CcSEcCtD
Gabapentin—BCAT1—Metabolism—SLC10A2—esophageal cancer	0.000891	0.0063	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—CA1—esophageal cancer	0.000891	0.0063	CbGpPWpGaD
Gabapentin—Irritability—Methotrexate—esophageal cancer	0.000872	0.00116	CcSEcCtD
Gabapentin—Convulsion—Cisplatin—esophageal cancer	0.000869	0.00116	CcSEcCtD
Gabapentin—Mood swings—Methotrexate—esophageal cancer	0.000866	0.00115	CcSEcCtD
Gabapentin—Bradycardia—Capecitabine—esophageal cancer	0.000865	0.00115	CcSEcCtD
Gabapentin—ADORA1—G alpha (i) signalling events—CXCL2—esophageal cancer	0.000862	0.00609	CbGpPWpGaD
Gabapentin—ADORA1—Circadian rythm related genes—GHRL—esophageal cancer	0.000861	0.00608	CbGpPWpGaD
Gabapentin—Ataxia—Methotrexate—esophageal cancer	0.000859	0.00114	CcSEcCtD
Gabapentin—Myalgia—Cisplatin—esophageal cancer	0.000854	0.00114	CcSEcCtD
Gabapentin—Rhinitis—Capecitabine—esophageal cancer	0.000852	0.00113	CcSEcCtD
Gabapentin—Anxiety—Cisplatin—esophageal cancer	0.000851	0.00113	CcSEcCtD
Gabapentin—Hepatitis—Capecitabine—esophageal cancer	0.000849	0.00113	CcSEcCtD
Gabapentin—Haemorrhage—Capecitabine—esophageal cancer	0.000849	0.00113	CcSEcCtD
Gabapentin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000848	0.00113	CcSEcCtD
Gabapentin—Hypoaesthesia—Capecitabine—esophageal cancer	0.000845	0.00113	CcSEcCtD
Gabapentin—Liver function test abnormal—Methotrexate—esophageal cancer	0.000844	0.00112	CcSEcCtD
Gabapentin—Discomfort—Cisplatin—esophageal cancer	0.000844	0.00112	CcSEcCtD
Gabapentin—Pharyngitis—Capecitabine—esophageal cancer	0.000843	0.00112	CcSEcCtD
Gabapentin—Urinary tract disorder—Capecitabine—esophageal cancer	0.000839	0.00112	CcSEcCtD
Gabapentin—Oedema peripheral—Capecitabine—esophageal cancer	0.000837	0.00111	CcSEcCtD
Gabapentin—Connective tissue disorder—Capecitabine—esophageal cancer	0.000835	0.00111	CcSEcCtD
Gabapentin—Urethral disorder—Capecitabine—esophageal cancer	0.000833	0.00111	CcSEcCtD
Gabapentin—Breast disorder—Methotrexate—esophageal cancer	0.000826	0.0011	CcSEcCtD
Gabapentin—Oedema—Cisplatin—esophageal cancer	0.000819	0.00109	CcSEcCtD
Gabapentin—Anaphylactic shock—Cisplatin—esophageal cancer	0.000819	0.00109	CcSEcCtD
Gabapentin—Visual impairment—Capecitabine—esophageal cancer	0.000819	0.00109	CcSEcCtD
Gabapentin—BCAT1—Metabolism—CA2—esophageal cancer	0.000815	0.00576	CbGpPWpGaD
Gabapentin—Infection—Cisplatin—esophageal cancer	0.000813	0.00108	CcSEcCtD
Gabapentin—Erythema multiforme—Capecitabine—esophageal cancer	0.000803	0.00107	CcSEcCtD
Gabapentin—Nervous system disorder—Cisplatin—esophageal cancer	0.000803	0.00107	CcSEcCtD
Gabapentin—Thrombocytopenia—Cisplatin—esophageal cancer	0.000802	0.00107	CcSEcCtD
Gabapentin—ADORA1—G alpha (i) signalling events—ANXA1—esophageal cancer	0.000801	0.00566	CbGpPWpGaD
Gabapentin—Tachycardia—Cisplatin—esophageal cancer	0.000799	0.00106	CcSEcCtD
Gabapentin—Skin disorder—Cisplatin—esophageal cancer	0.000795	0.00106	CcSEcCtD
Gabapentin—Eye disorder—Capecitabine—esophageal cancer	0.000794	0.00106	CcSEcCtD
Gabapentin—Tinnitus—Capecitabine—esophageal cancer	0.000792	0.00105	CcSEcCtD
Gabapentin—Hyperhidrosis—Cisplatin—esophageal cancer	0.000791	0.00105	CcSEcCtD
Gabapentin—Asthma—Methotrexate—esophageal cancer	0.00079	0.00105	CcSEcCtD
Gabapentin—Cardiac disorder—Capecitabine—esophageal cancer	0.000788	0.00105	CcSEcCtD
Gabapentin—Eosinophilia—Methotrexate—esophageal cancer	0.000782	0.00104	CcSEcCtD
Gabapentin—Anorexia—Cisplatin—esophageal cancer	0.00078	0.00104	CcSEcCtD
Gabapentin—ADORA1—G alpha (i) signalling events—SST—esophageal cancer	0.000779	0.00551	CbGpPWpGaD
Gabapentin—Pancreatitis—Methotrexate—esophageal cancer	0.000774	0.00103	CcSEcCtD
Gabapentin—Immune system disorder—Capecitabine—esophageal cancer	0.000767	0.00102	CcSEcCtD
Gabapentin—Mediastinal disorder—Capecitabine—esophageal cancer	0.000765	0.00102	CcSEcCtD
Gabapentin—Hypotension—Cisplatin—esophageal cancer	0.000765	0.00102	CcSEcCtD
Gabapentin—Chills—Capecitabine—esophageal cancer	0.000762	0.00101	CcSEcCtD
Gabapentin—BCAT1—Metabolism—ADH7—esophageal cancer	0.000758	0.00535	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—PLCE1—esophageal cancer	0.000758	0.00535	CbGpPWpGaD
Gabapentin—Alopecia—Capecitabine—esophageal cancer	0.000751	0.001	CcSEcCtD
Gabapentin—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000746	0.000993	CcSEcCtD
Gabapentin—Mental disorder—Capecitabine—esophageal cancer	0.000744	0.000991	CcSEcCtD
Gabapentin—Malnutrition—Capecitabine—esophageal cancer	0.000739	0.000985	CcSEcCtD
Gabapentin—Erythema—Capecitabine—esophageal cancer	0.000739	0.000985	CcSEcCtD
Gabapentin—Dysuria—Methotrexate—esophageal cancer	0.000739	0.000984	CcSEcCtD
Gabapentin—Paraesthesia—Cisplatin—esophageal cancer	0.000735	0.000979	CcSEcCtD
Gabapentin—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000734	0.000978	CcSEcCtD
Gabapentin—Dyspnoea—Cisplatin—esophageal cancer	0.00073	0.000972	CcSEcCtD
Gabapentin—Flatulence—Capecitabine—esophageal cancer	0.000729	0.00097	CcSEcCtD
Gabapentin—Erectile dysfunction—Methotrexate—esophageal cancer	0.000728	0.000969	CcSEcCtD
Gabapentin—Dysgeusia—Capecitabine—esophageal cancer	0.000724	0.000964	CcSEcCtD
Gabapentin—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000721	0.00096	CcSEcCtD
Gabapentin—Back pain—Capecitabine—esophageal cancer	0.000715	0.000952	CcSEcCtD
Gabapentin—Decreased appetite—Cisplatin—esophageal cancer	0.000712	0.000948	CcSEcCtD
Gabapentin—Muscle spasms—Capecitabine—esophageal cancer	0.000711	0.000947	CcSEcCtD
Gabapentin—Pneumonia—Methotrexate—esophageal cancer	0.000708	0.000943	CcSEcCtD
Gabapentin—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000707	0.000941	CcSEcCtD
Gabapentin—Drowsiness—Methotrexate—esophageal cancer	0.000704	0.000938	CcSEcCtD
Gabapentin—Infestation—Methotrexate—esophageal cancer	0.000704	0.000938	CcSEcCtD
Gabapentin—Infestation NOS—Methotrexate—esophageal cancer	0.000704	0.000938	CcSEcCtD
Gabapentin—Depression—Methotrexate—esophageal cancer	0.000702	0.000935	CcSEcCtD
Gabapentin—Pain—Cisplatin—esophageal cancer	0.0007	0.000932	CcSEcCtD
Gabapentin—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000698	0.00093	CcSEcCtD
Gabapentin—Vision blurred—Capecitabine—esophageal cancer	0.000697	0.000928	CcSEcCtD
Gabapentin—Tremor—Capecitabine—esophageal cancer	0.000693	0.000923	CcSEcCtD
Gabapentin—Renal failure—Methotrexate—esophageal cancer	0.000692	0.000922	CcSEcCtD
Gabapentin—Stomatitis—Methotrexate—esophageal cancer	0.000687	0.000914	CcSEcCtD
Gabapentin—Ill-defined disorder—Capecitabine—esophageal cancer	0.000686	0.000914	CcSEcCtD
Gabapentin—ADORA1—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000685	0.00484	CbGpPWpGaD
Gabapentin—Conjunctivitis—Methotrexate—esophageal cancer	0.000685	0.000912	CcSEcCtD
Gabapentin—Anaemia—Capecitabine—esophageal cancer	0.000683	0.00091	CcSEcCtD
Gabapentin—Sweating—Methotrexate—esophageal cancer	0.000675	0.000899	CcSEcCtD
Gabapentin—Feeling abnormal—Cisplatin—esophageal cancer	0.000675	0.000898	CcSEcCtD
Gabapentin—Haematuria—Methotrexate—esophageal cancer	0.000672	0.000894	CcSEcCtD
Gabapentin—Malaise—Capecitabine—esophageal cancer	0.000667	0.000888	CcSEcCtD
Gabapentin—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000666	0.000887	CcSEcCtD
Gabapentin—Epistaxis—Methotrexate—esophageal cancer	0.000664	0.000885	CcSEcCtD
Gabapentin—Vertigo—Capecitabine—esophageal cancer	0.000664	0.000885	CcSEcCtD
Gabapentin—BCAT1—Metabolism—ADH1B—esophageal cancer	0.000664	0.00469	CbGpPWpGaD
Gabapentin—Syncope—Capecitabine—esophageal cancer	0.000663	0.000883	CcSEcCtD
Gabapentin—Leukopenia—Capecitabine—esophageal cancer	0.000662	0.000881	CcSEcCtD
Gabapentin—Palpitations—Capecitabine—esophageal cancer	0.000653	0.00087	CcSEcCtD
Gabapentin—Loss of consciousness—Capecitabine—esophageal cancer	0.00065	0.000865	CcSEcCtD
Gabapentin—Body temperature increased—Cisplatin—esophageal cancer	0.000647	0.000862	CcSEcCtD
Gabapentin—Cough—Capecitabine—esophageal cancer	0.000645	0.000859	CcSEcCtD
Gabapentin—Hypertension—Capecitabine—esophageal cancer	0.000638	0.00085	CcSEcCtD
Gabapentin—ADORA1—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000637	0.0045	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—SLC52A3—esophageal cancer	0.000635	0.00449	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—BLVRB—esophageal cancer	0.000635	0.00449	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—TYMP—esophageal cancer	0.000635	0.00449	CbGpPWpGaD
Gabapentin—Haemorrhage—Methotrexate—esophageal cancer	0.000632	0.000842	CcSEcCtD
Gabapentin—Hepatitis—Methotrexate—esophageal cancer	0.000632	0.000842	CcSEcCtD
Gabapentin—Chest pain—Capecitabine—esophageal cancer	0.000629	0.000838	CcSEcCtD
Gabapentin—Myalgia—Capecitabine—esophageal cancer	0.000629	0.000838	CcSEcCtD
Gabapentin—Arthralgia—Capecitabine—esophageal cancer	0.000629	0.000838	CcSEcCtD
Gabapentin—Pharyngitis—Methotrexate—esophageal cancer	0.000628	0.000836	CcSEcCtD
Gabapentin—Anxiety—Capecitabine—esophageal cancer	0.000627	0.000835	CcSEcCtD
Gabapentin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000625	0.000833	CcSEcCtD
Gabapentin—Urinary tract disorder—Methotrexate—esophageal cancer	0.000624	0.000832	CcSEcCtD
Gabapentin—Discomfort—Capecitabine—esophageal cancer	0.000622	0.000828	CcSEcCtD
Gabapentin—Urethral disorder—Methotrexate—esophageal cancer	0.00062	0.000825	CcSEcCtD
Gabapentin—ADORA1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00062	0.00438	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—CYP26A1—esophageal cancer	0.000618	0.00436	CbGpPWpGaD
Gabapentin—Dry mouth—Capecitabine—esophageal cancer	0.000616	0.00082	CcSEcCtD
Gabapentin—Visual impairment—Methotrexate—esophageal cancer	0.000609	0.000811	CcSEcCtD
Gabapentin—Confusional state—Capecitabine—esophageal cancer	0.000608	0.00081	CcSEcCtD
Gabapentin—ADORA1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000604	0.00427	CbGpPWpGaD
Gabapentin—Oedema—Capecitabine—esophageal cancer	0.000603	0.000804	CcSEcCtD
Gabapentin—Hypersensitivity—Cisplatin—esophageal cancer	0.000603	0.000803	CcSEcCtD
Gabapentin—BCAT1—Metabolism—ALOX15—esophageal cancer	0.000602	0.00425	CbGpPWpGaD
Gabapentin—Infection—Capecitabine—esophageal cancer	0.0006	0.000798	CcSEcCtD
Gabapentin—Erythema multiforme—Methotrexate—esophageal cancer	0.000598	0.000796	CcSEcCtD
Gabapentin—ADORA1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000597	0.00422	CbGpPWpGaD
Gabapentin—Shock—Capecitabine—esophageal cancer	0.000594	0.000791	CcSEcCtD
Gabapentin—ADORA1—GPCR ligand binding—GNG7—esophageal cancer	0.000592	0.00419	CbGpPWpGaD
Gabapentin—Nervous system disorder—Capecitabine—esophageal cancer	0.000592	0.000788	CcSEcCtD
Gabapentin—Eye disorder—Methotrexate—esophageal cancer	0.000591	0.000787	CcSEcCtD
Gabapentin—Thrombocytopenia—Capecitabine—esophageal cancer	0.000591	0.000787	CcSEcCtD
Gabapentin—Tinnitus—Methotrexate—esophageal cancer	0.00059	0.000785	CcSEcCtD
Gabapentin—Tachycardia—Capecitabine—esophageal cancer	0.000589	0.000784	CcSEcCtD
Gabapentin—Asthenia—Cisplatin—esophageal cancer	0.000587	0.000782	CcSEcCtD
Gabapentin—Cardiac disorder—Methotrexate—esophageal cancer	0.000587	0.000781	CcSEcCtD
Gabapentin—Skin disorder—Capecitabine—esophageal cancer	0.000586	0.000781	CcSEcCtD
Gabapentin—Hyperhidrosis—Capecitabine—esophageal cancer	0.000583	0.000777	CcSEcCtD
Gabapentin—Anorexia—Capecitabine—esophageal cancer	0.000575	0.000766	CcSEcCtD
Gabapentin—BCAT1—Metabolism—GSTO1—esophageal cancer	0.000574	0.00406	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—TPI1—esophageal cancer	0.000574	0.00406	CbGpPWpGaD
Gabapentin—Immune system disorder—Methotrexate—esophageal cancer	0.000571	0.000761	CcSEcCtD
Gabapentin—Mediastinal disorder—Methotrexate—esophageal cancer	0.00057	0.000759	CcSEcCtD
Gabapentin—Chills—Methotrexate—esophageal cancer	0.000567	0.000756	CcSEcCtD
Gabapentin—Hypotension—Capecitabine—esophageal cancer	0.000564	0.000751	CcSEcCtD
Gabapentin—Diarrhoea—Cisplatin—esophageal cancer	0.00056	0.000746	CcSEcCtD
Gabapentin—Alopecia—Methotrexate—esophageal cancer	0.000559	0.000744	CcSEcCtD
Gabapentin—Mental disorder—Methotrexate—esophageal cancer	0.000554	0.000738	CcSEcCtD
Gabapentin—Malnutrition—Methotrexate—esophageal cancer	0.00055	0.000733	CcSEcCtD
Gabapentin—Erythema—Methotrexate—esophageal cancer	0.00055	0.000733	CcSEcCtD
Gabapentin—BCAT1—Metabolism—ALDOB—esophageal cancer	0.00055	0.00389	CbGpPWpGaD
Gabapentin—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00055	0.000732	CcSEcCtD
Gabapentin—Insomnia—Capecitabine—esophageal cancer	0.000546	0.000727	CcSEcCtD
Gabapentin—ADORA1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000542	0.00383	CbGpPWpGaD
Gabapentin—Paraesthesia—Capecitabine—esophageal cancer	0.000542	0.000722	CcSEcCtD
Gabapentin—CACNA2D2—Metabolism—SLC10A2—esophageal cancer	0.00054	0.00381	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—CA1—esophageal cancer	0.00054	0.00381	CbGpPWpGaD
Gabapentin—Dysgeusia—Methotrexate—esophageal cancer	0.000539	0.000718	CcSEcCtD
Gabapentin—Dyspnoea—Capecitabine—esophageal cancer	0.000538	0.000716	CcSEcCtD
Gabapentin—Back pain—Methotrexate—esophageal cancer	0.000532	0.000709	CcSEcCtD
Gabapentin—Dyspepsia—Capecitabine—esophageal cancer	0.000531	0.000707	CcSEcCtD
Gabapentin—BCAT1—Metabolism—GAPDH—esophageal cancer	0.00053	0.00374	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—CRABP1—esophageal cancer	0.000525	0.00371	CbGpPWpGaD
Gabapentin—Decreased appetite—Capecitabine—esophageal cancer	0.000525	0.000699	CcSEcCtD
Gabapentin—ADORA1—GPCR ligand binding—CXCL2—esophageal cancer	0.000522	0.00369	CbGpPWpGaD
Gabapentin—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000521	0.000694	CcSEcCtD
Gabapentin—Vomiting—Cisplatin—esophageal cancer	0.00052	0.000693	CcSEcCtD
Gabapentin—Fatigue—Capecitabine—esophageal cancer	0.00052	0.000693	CcSEcCtD
Gabapentin—Vision blurred—Methotrexate—esophageal cancer	0.000519	0.000691	CcSEcCtD
Gabapentin—Rash—Cisplatin—esophageal cancer	0.000516	0.000687	CcSEcCtD
Gabapentin—Pain—Capecitabine—esophageal cancer	0.000516	0.000687	CcSEcCtD
Gabapentin—Constipation—Capecitabine—esophageal cancer	0.000516	0.000687	CcSEcCtD
Gabapentin—Dermatitis—Cisplatin—esophageal cancer	0.000516	0.000687	CcSEcCtD
Gabapentin—Ill-defined disorder—Methotrexate—esophageal cancer	0.000511	0.00068	CcSEcCtD
Gabapentin—Anaemia—Methotrexate—esophageal cancer	0.000509	0.000677	CcSEcCtD
Gabapentin—BCAT1—Metabolism—GNG7—esophageal cancer	0.000499	0.00353	CbGpPWpGaD
Gabapentin—Feeling abnormal—Capecitabine—esophageal cancer	0.000497	0.000662	CcSEcCtD
Gabapentin—ADORA1—Signaling Pathways—GDI2—esophageal cancer	0.000497	0.00351	CbGpPWpGaD
Gabapentin—Malaise—Methotrexate—esophageal cancer	0.000496	0.000661	CcSEcCtD
Gabapentin—Vertigo—Methotrexate—esophageal cancer	0.000495	0.000659	CcSEcCtD
Gabapentin—CACNA2D2—Metabolism—CA2—esophageal cancer	0.000494	0.00349	CbGpPWpGaD
Gabapentin—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000493	0.000657	CcSEcCtD
Gabapentin—Leukopenia—Methotrexate—esophageal cancer	0.000493	0.000656	CcSEcCtD
Gabapentin—Nausea—Cisplatin—esophageal cancer	0.000486	0.000648	CcSEcCtD
Gabapentin—ADORA1—GPCR ligand binding—ANXA1—esophageal cancer	0.000485	0.00343	CbGpPWpGaD
Gabapentin—ADORA1—Circadian rythm related genes—NOS2—esophageal cancer	0.000482	0.00341	CbGpPWpGaD
Gabapentin—Cough—Methotrexate—esophageal cancer	0.00048	0.00064	CcSEcCtD
Gabapentin—Urticaria—Capecitabine—esophageal cancer	0.000479	0.000638	CcSEcCtD
Gabapentin—Body temperature increased—Capecitabine—esophageal cancer	0.000477	0.000635	CcSEcCtD
Gabapentin—Abdominal pain—Capecitabine—esophageal cancer	0.000477	0.000635	CcSEcCtD
Gabapentin—Convulsion—Methotrexate—esophageal cancer	0.000477	0.000635	CcSEcCtD
Gabapentin—ADORA1—GPCR ligand binding—SST—esophageal cancer	0.000472	0.00333	CbGpPWpGaD
Gabapentin—Myalgia—Methotrexate—esophageal cancer	0.000469	0.000624	CcSEcCtD
Gabapentin—Arthralgia—Methotrexate—esophageal cancer	0.000469	0.000624	CcSEcCtD
Gabapentin—Chest pain—Methotrexate—esophageal cancer	0.000469	0.000624	CcSEcCtD
Gabapentin—BCAT1—Metabolism—ALDH2—esophageal cancer	0.000468	0.00331	CbGpPWpGaD
Gabapentin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000465	0.00062	CcSEcCtD
Gabapentin—Discomfort—Methotrexate—esophageal cancer	0.000463	0.000617	CcSEcCtD
Gabapentin—ADORA1—GPCR ligand binding—GHRL—esophageal cancer	0.00046	0.00325	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—PLCE1—esophageal cancer	0.000459	0.00324	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—ADH7—esophageal cancer	0.000459	0.00324	CbGpPWpGaD
Gabapentin—Confusional state—Methotrexate—esophageal cancer	0.000453	0.000603	CcSEcCtD
Gabapentin—Anaphylactic shock—Methotrexate—esophageal cancer	0.000449	0.000598	CcSEcCtD
Gabapentin—Infection—Methotrexate—esophageal cancer	0.000446	0.000594	CcSEcCtD
Gabapentin—BCAT1—Metabolism—GSTT1—esophageal cancer	0.000445	0.00315	CbGpPWpGaD
Gabapentin—Hypersensitivity—Capecitabine—esophageal cancer	0.000445	0.000592	CcSEcCtD
Gabapentin—Nervous system disorder—Methotrexate—esophageal cancer	0.000441	0.000587	CcSEcCtD
Gabapentin—BCAT1—Metabolism—CYP2A6—esophageal cancer	0.00044	0.00311	CbGpPWpGaD
Gabapentin—Thrombocytopenia—Methotrexate—esophageal cancer	0.00044	0.000586	CcSEcCtD
Gabapentin—Skin disorder—Methotrexate—esophageal cancer	0.000436	0.000581	CcSEcCtD
Gabapentin—Hyperhidrosis—Methotrexate—esophageal cancer	0.000434	0.000578	CcSEcCtD
Gabapentin—Asthenia—Capecitabine—esophageal cancer	0.000433	0.000577	CcSEcCtD
Gabapentin—Anorexia—Methotrexate—esophageal cancer	0.000428	0.00057	CcSEcCtD
Gabapentin—Pruritus—Capecitabine—esophageal cancer	0.000427	0.000569	CcSEcCtD
Gabapentin—Hypotension—Methotrexate—esophageal cancer	0.00042	0.000559	CcSEcCtD
Gabapentin—BCAT1—Metabolism—ENO1—esophageal cancer	0.000417	0.00295	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—PTGS1—esophageal cancer	0.000417	0.00295	CbGpPWpGaD
Gabapentin—Diarrhoea—Capecitabine—esophageal cancer	0.000413	0.00055	CcSEcCtD
Gabapentin—BCAT1—Metabolism—PSME2—esophageal cancer	0.000411	0.0029	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—PSME1—esophageal cancer	0.000411	0.0029	CbGpPWpGaD
Gabapentin—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000409	0.000545	CcSEcCtD
Gabapentin—Insomnia—Methotrexate—esophageal cancer	0.000406	0.000541	CcSEcCtD
Gabapentin—Paraesthesia—Methotrexate—esophageal cancer	0.000403	0.000537	CcSEcCtD
Gabapentin—CACNA2D2—Metabolism—ADH1B—esophageal cancer	0.000402	0.00284	CbGpPWpGaD
Gabapentin—Dyspnoea—Methotrexate—esophageal cancer	0.0004	0.000533	CcSEcCtD
Gabapentin—Somnolence—Methotrexate—esophageal cancer	0.000399	0.000532	CcSEcCtD
Gabapentin—Dizziness—Capecitabine—esophageal cancer	0.000399	0.000531	CcSEcCtD
Gabapentin—Dyspepsia—Methotrexate—esophageal cancer	0.000395	0.000527	CcSEcCtD
Gabapentin—Decreased appetite—Methotrexate—esophageal cancer	0.000391	0.00052	CcSEcCtD
Gabapentin—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000388	0.000516	CcSEcCtD
Gabapentin—Fatigue—Methotrexate—esophageal cancer	0.000387	0.000516	CcSEcCtD
Gabapentin—ADORA1—GPCR downstream signaling—AKAP13—esophageal cancer	0.000385	0.00272	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—TYMP—esophageal cancer	0.000385	0.00272	CbGpPWpGaD
Gabapentin—Pain—Methotrexate—esophageal cancer	0.000384	0.000512	CcSEcCtD
Gabapentin—Vomiting—Capecitabine—esophageal cancer	0.000384	0.000511	CcSEcCtD
Gabapentin—Rash—Capecitabine—esophageal cancer	0.00038	0.000507	CcSEcCtD
Gabapentin—Dermatitis—Capecitabine—esophageal cancer	0.00038	0.000506	CcSEcCtD
Gabapentin—Headache—Capecitabine—esophageal cancer	0.000378	0.000503	CcSEcCtD
Gabapentin—CACNA2D2—Metabolism—CYP26A1—esophageal cancer	0.000374	0.00264	CbGpPWpGaD
Gabapentin—Feeling abnormal—Methotrexate—esophageal cancer	0.00037	0.000493	CcSEcCtD
Gabapentin—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000367	0.000489	CcSEcCtD
Gabapentin—CACNA2D2—Metabolism—ALOX15—esophageal cancer	0.000365	0.00258	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—KMT2D—esophageal cancer	0.000359	0.00254	CbGpPWpGaD
Gabapentin—Nausea—Capecitabine—esophageal cancer	0.000358	0.000477	CcSEcCtD
Gabapentin—Urticaria—Methotrexate—esophageal cancer	0.000357	0.000475	CcSEcCtD
Gabapentin—Body temperature increased—Methotrexate—esophageal cancer	0.000355	0.000473	CcSEcCtD
Gabapentin—Abdominal pain—Methotrexate—esophageal cancer	0.000355	0.000473	CcSEcCtD
Gabapentin—BCAT1—Metabolism—CYP1B1—esophageal cancer	0.000355	0.00251	CbGpPWpGaD
Gabapentin—ADORA1—GPCR downstream signaling—PDE4D—esophageal cancer	0.000352	0.00249	CbGpPWpGaD
Gabapentin—ADORA1—Signaling by GPCR—AKAP13—esophageal cancer	0.000349	0.00247	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—GSTO1—esophageal cancer	0.000348	0.00246	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—TPI1—esophageal cancer	0.000348	0.00246	CbGpPWpGaD
Gabapentin—ADORA1—GPCR downstream signaling—GNG7—esophageal cancer	0.000335	0.00237	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—ALDOB—esophageal cancer	0.000333	0.00236	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—CYP19A1—esophageal cancer	0.000333	0.00236	CbGpPWpGaD
Gabapentin—Hypersensitivity—Methotrexate—esophageal cancer	0.000331	0.000441	CcSEcCtD
Gabapentin—Asthenia—Methotrexate—esophageal cancer	0.000322	0.000429	CcSEcCtD
Gabapentin—CACNA2D2—Metabolism—GAPDH—esophageal cancer	0.000321	0.00227	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—ADCYAP1—esophageal cancer	0.00032	0.00226	CbGpPWpGaD
Gabapentin—ADORA1—Signaling by GPCR—PDE4D—esophageal cancer	0.00032	0.00226	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—CRABP1—esophageal cancer	0.000318	0.00225	CbGpPWpGaD
Gabapentin—Pruritus—Methotrexate—esophageal cancer	0.000318	0.000423	CcSEcCtD
Gabapentin—Diarrhoea—Methotrexate—esophageal cancer	0.000307	0.000409	CcSEcCtD
Gabapentin—BCAT1—Metabolism—HMOX1—esophageal cancer	0.000304	0.00215	CbGpPWpGaD
Gabapentin—ADORA1—Signaling by GPCR—GNG7—esophageal cancer	0.000304	0.00215	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—GNG7—esophageal cancer	0.000303	0.00214	CbGpPWpGaD
Gabapentin—Dizziness—Methotrexate—esophageal cancer	0.000297	0.000396	CcSEcCtD
Gabapentin—ADORA1—Circadian rythm related genes—EP300—esophageal cancer	0.000295	0.00209	CbGpPWpGaD
Gabapentin—ADORA1—GPCR downstream signaling—CXCL2—esophageal cancer	0.000295	0.00208	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—WWOX—esophageal cancer	0.000293	0.00207	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—ABCB1—esophageal cancer	0.000292	0.00206	CbGpPWpGaD
Gabapentin—Vomiting—Methotrexate—esophageal cancer	0.000286	0.00038	CcSEcCtD
Gabapentin—CACNA2D2—Metabolism—ALDH2—esophageal cancer	0.000284	0.002	CbGpPWpGaD
Gabapentin—Rash—Methotrexate—esophageal cancer	0.000283	0.000377	CcSEcCtD
Gabapentin—Dermatitis—Methotrexate—esophageal cancer	0.000283	0.000377	CcSEcCtD
Gabapentin—Headache—Methotrexate—esophageal cancer	0.000281	0.000375	CcSEcCtD
Gabapentin—ADORA1—Signaling Pathways—FKBP1A—esophageal cancer	0.000279	0.00197	CbGpPWpGaD
Gabapentin—ADORA1—GPCR downstream signaling—ANXA1—esophageal cancer	0.000274	0.00194	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—WIF1—esophageal cancer	0.000272	0.00192	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—GSTT1—esophageal cancer	0.00027	0.00191	CbGpPWpGaD
Gabapentin—ADORA1—Signaling by GPCR—CXCL2—esophageal cancer	0.000268	0.00189	CbGpPWpGaD
Gabapentin—Nausea—Methotrexate—esophageal cancer	0.000267	0.000355	CcSEcCtD
Gabapentin—ADORA1—GPCR downstream signaling—SST—esophageal cancer	0.000267	0.00188	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—CYP2A6—esophageal cancer	0.000267	0.00188	CbGpPWpGaD
Gabapentin—ADORA1—GPCR downstream signaling—GHRL—esophageal cancer	0.00026	0.00184	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—ENO1—esophageal cancer	0.000253	0.00179	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—PTGS1—esophageal cancer	0.000253	0.00179	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000251	0.00178	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—PSME1—esophageal cancer	0.000249	0.00176	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—PSME2—esophageal cancer	0.000249	0.00176	CbGpPWpGaD
Gabapentin—ADORA1—Signaling by GPCR—ANXA1—esophageal cancer	0.000249	0.00176	CbGpPWpGaD
Gabapentin—ADORA1—Signaling by GPCR—SST—esophageal cancer	0.000242	0.00171	CbGpPWpGaD
Gabapentin—ADORA1—Signaling by GPCR—GHRL—esophageal cancer	0.000236	0.00167	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—PFN1—esophageal cancer	0.000235	0.00166	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—CYP1B1—esophageal cancer	0.000215	0.00152	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—ELMO1—esophageal cancer	0.000211	0.00149	CbGpPWpGaD
Gabapentin—ADORA1—Circadian rythm related genes—TP53—esophageal cancer	0.000211	0.00149	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—AKAP13—esophageal cancer	0.000206	0.00146	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—CYP19A1—esophageal cancer	0.000202	0.00143	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—CREBBP—esophageal cancer	0.000195	0.00138	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.00019	0.00135	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—PDE4D—esophageal cancer	0.000189	0.00133	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—HMOX1—esophageal cancer	0.000184	0.0013	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—GNG7—esophageal cancer	0.00018	0.00127	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—ABCB1—esophageal cancer	0.000177	0.00125	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—NOS3—esophageal cancer	0.000175	0.00124	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—XIAP—esophageal cancer	0.000168	0.00119	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—PTGS2—esophageal cancer	0.00016	0.00113	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—CTNNA1—esophageal cancer	0.000159	0.00112	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—CXCL2—esophageal cancer	0.000158	0.00112	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—PSME2—esophageal cancer	0.000148	0.00104	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—PSME1—esophageal cancer	0.000148	0.00104	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—ANXA1—esophageal cancer	0.000147	0.00104	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—SST—esophageal cancer	0.000143	0.00101	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—NOTCH3—esophageal cancer	0.000139	0.000985	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—GHRL—esophageal cancer	0.000139	0.000985	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—FBXW7—esophageal cancer	0.000137	0.000969	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—EP300—esophageal cancer	0.000133	0.000939	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—NOTCH2—esophageal cancer	0.000125	0.000884	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—CREBBP—esophageal cancer	0.000118	0.000836	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—TGFBR2—esophageal cancer	0.000111	0.000784	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—NOS3—esophageal cancer	0.000106	0.000748	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—SMAD4—esophageal cancer	0.000105	0.000742	CbGpPWpGaD
Gabapentin—BCAT1—Metabolism—PIK3CA—esophageal cancer	9.83e-05	0.000695	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—PTGS2—esophageal cancer	9.68e-05	0.000684	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—HIF1A—esophageal cancer	8.59e-05	0.000607	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—KDR—esophageal cancer	8.22e-05	0.000581	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—EP300—esophageal cancer	8.05e-05	0.000569	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—NOTCH1—esophageal cancer	7.74e-05	0.000547	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—CREBBP—esophageal cancer	7.02e-05	0.000496	CbGpPWpGaD
Gabapentin—ADORA1—Signaling by GPCR—EGFR—esophageal cancer	6.9e-05	0.000487	CbGpPWpGaD
Gabapentin—ADORA1—GPCR downstream signaling—PIK3CA—esophageal cancer	6.59e-05	0.000466	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—NOS3—esophageal cancer	6.28e-05	0.000444	CbGpPWpGaD
Gabapentin—ADORA1—Signaling by GPCR—PIK3CA—esophageal cancer	5.99e-05	0.000423	CbGpPWpGaD
Gabapentin—CACNA2D2—Metabolism—PIK3CA—esophageal cancer	5.96e-05	0.000421	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—ERBB2—esophageal cancer	5.88e-05	0.000415	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—CCND1—esophageal cancer	5.19e-05	0.000367	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—CDKN1A—esophageal cancer	5.02e-05	0.000355	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—EP300—esophageal cancer	4.78e-05	0.000338	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—MYC—esophageal cancer	4.16e-05	0.000294	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—EGFR—esophageal cancer	4.07e-05	0.000288	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—PIK3CA—esophageal cancer	3.54e-05	0.00025	CbGpPWpGaD
Gabapentin—ADORA1—Signaling Pathways—TP53—esophageal cancer	3.42e-05	0.000242	CbGpPWpGaD
